Impact of follow-up visits on disease outcome in Chinese systemic lupus erythematosus
Tóm tắt
The objective of this study is to determine whether the frequency of visits would affect disease activity and disease damage in patients with systemic lupus erythematosus (SLE). We recruited 147 patients who met the 1997 American College of Rheumatology (ACR) criteria for SLE. Patients were divided into three groups based on follow-up frequency: ≤ 6 visits/year (group 1), 6–12 visits/year (group 2), and > 12 visits/year (group 3). Disease activity and organ damage were evaluated using the SLE disease activity index (SLEDAI) and Systemic Lupus International Collaborative Clinics (SLICC)/ACR criteria, respectively. Data on disease features, patient characteristics, and treatment were retrospectively reviewed. We found that the SLICC score was significantly lower in patients with > 12 visits/year (P = 0.008), while the SLEDAI score showed no significant difference. The age at symptom onset (32.68 ± 13.53) and the age at SLE diagnosis (33.32 ± 13.81) in group 3 were significantly older than those in the other two groups. In univariate regression analysis, the frequency of visits, the age at symptom onset, and the age at SLE diagnosis were found to be associated with the SLICC scores. Visit frequency has no impact on SLE disease activity, but may be associated with less disease damage, an important outcome.
Tài liệu tham khảo
Li LH, Pan HF, Li WX, Li XP, Xu JH, Ye DQ (2009) Study on clinical features and complications with systemic lupus erythematosus (SLE) activity in Chinese Han population. Clin Rheumatol 28(11):1301–1307
Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, Maclean CH, Wofsy D et al (2009) A quality indicator set for systemic lupus erythematosus. Arthritis Rheum 61(3):370
Morand EF (2016) Connective tissue diseases: remission in SLE—are we there yet? Nat Rev Rheumatol 12(12):696–698
Ruiz E, Ramallegómara E, Elena Á, Quiñones C, Alonso V, Posada M (2014) Trends in systemic lupus erythematosus mortality in Spain from 1981 to 2010. Lupus 23(4):431–435
Shen HN, Yang HH, Lu CL (2013) Temporal trends in characteristics and outcome of intensive care unit patients with systemic lupus erythematosus in Taiwan: a national population-based study. Lupus 22(6):644–652
Wu G, Jia X, Gao D, Zhao Z (2014) Survival rates and risk factors for mortality in systemic lupus erythematosus patients in a Chinese center. Clin Rheumatol 33(7):947–953
Urowitz MB, Gladman D, Abushakra M, Farewell VT (1997) Mortality studies in systemic lupus erythematosus. Results from a single center. iii. Improved survival over 24 years. J Rheumatol 24(6):1061–1065
Urowitz MB, Kagal A, Rahman P, Gladman DD (2002) Role of specialty care in the management of patients with systemic lupus erythematosus. J Rheumatol 29(6):1207–1210
Wallace DJ (2008) Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox. Lupus 17(2):91–92
Drenkard C, Villa AR, Garciapadilla C, Pérezvázquez ME, Alarcónsegovia D (1996) Remission of systematic lupus erythematosus. Medicine 75(2):88–98
Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Sanchez-Guerrero J et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39(3):363–369
Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E et al (2000) The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol 27(2):373
Listed N (1999) Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology ad hoc committee on systemic lupus erythematosus guidelines. Arthritis Rheum 42(9):1785
Gladman DD, Koh DR, Urowitz MB, Farewell VT (2000) Lost-to-follow-up study in systemic lupus erythematosus (SLE). Lupus 9(5):363–367
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–640
Tunnicliffe DJ, Singhgrewal D, Kim S, Craig JC, Tong A (2015) Diagnosis, monitoring and treatment of systemic lupus erythematosus: a systematic review of clinical practice guidelines. Arthritis Care Res 67(10):1440–1452
Doria A, Zen M, Canova M, Bettio S, Bassi N, Nalotto L et al (2010) SLE diagnosis and treatment: when early is early. Autoimmun Rev 10(1):55–60
Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, Guern VL, Leroux G, Marra D et al (2013) Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 27(3):329–340
Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Cervera R et al (2011) Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev 10(7):383
Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R et al (2010) European league against rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 69(7):1269–1274
Gladman DD, Ibañez D, Ruiz I, Urowitz MB (2013) Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. J Rheumatol 40(5):630–633
Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR (2013) The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol 40(6):831–841
Yazdany J, Trupin L, Schmajuk G, Katz PP, Yelin EH (2014) Quality of care in systemic lupus erythematosus: the association between process and outcome measures in the lupus outcomes study. BMJ Qual Saf 23(8):659–666
Ibañez D, Gladman DD, Touma Z, Nikpour M, Urowitz MB (2011) Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time. J Rheumatol 38(1):60
Bertoli AM, Fernández M, Calvo-Alén J, Vilá LM, Sanchez ML, Reveille JD et al (2006) Systemic lupus erythematosus in a multiethnic US cohort (lumina) xxxi: factors associated with patients being lost to follow-up. Lupus 15(1):19–25
Tien YC, Chiu YM, Liu MP (2016) Frequency of lost to follow-up and associated factors for patients with rheumatic diseases. PLoS One 11(3):e0150816
Yazdany J, Gillis JZ, Trupin L, Katz P, Panopalis P, Criswell LA et al (2007) Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in systemic lupus erythematosus. Arthritis Care Res 57(4):593–600
Kulczycka L, Sysa-Jędrzejowska A, Robak E (2010) Quality of life and satisfaction with life in SLE patients-the importance of clinical manifestations. Clin Rheumatol 29(9):991–997
Daleboudt GM, Broadbent E, Mcqueen F, Kaptein AA (2011) Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus. Arthritis Care Res 63(3):342